AzurRx BioPharma
 | |
| | |
| AzurRx BioPharma | |
|---|---|
| Type | Public |
| Industry | Pharmaceutical |
| Founded | 2014 |
| Headquarters | Brooklyn, NY |
| Key people | Thijs Spoor(President), Daniel Dupret(Chief Scientific Officer), George Harb(MD)[1] |
| Investors | WallachBeth Capital and Network 1 Financial Securities[2][3] |
| Number of employees | 12 [4] |
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders[5]. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant ß-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is based in Brooklyn, New York.AzurRx BioPharma is developing a treatment for pancreatic insufficiency with the scientific backing of European biopharma researchers, it has earned Phase 1 clinical trial success for its lead candidate.[6]
Contents
History
- July 31, 2014, AzurRx announces issuance of U.S. Patent for its MS1819 lipase compound.[7]
- May 28, 2015, AzurRx announces addition of Ed Borkowski to the Board of Directors.[8]
- January 11, 2016, AzurRx President Thijs Spoor made a presentation at the 8th Annual Biotech Showcase 2016 meeting in San Francisco.[9]
- AzurRX and Protea Biosciences Group, Inc. and its wholly owned subsidiary Protea Biosciences, Inc. entered into a stock purchase and sale agreement with AzurRx BioPharma, Inc.[10][11]
- October 12, 2016, AzurRx BioPharma Inc. announced that its initial public offering of 960,000 shares of common stock has been priced at $5.50 per share.[12][13]
- October 12, 2016, AzurRX had to dip under its lowest range of $6 to $8 to just $5.50, raising $5 million through just under 1 million shares.[14]
- October 19, 2016, AzurRx BioPharma Inc. to ring the Nasdaq stock market Closing Bell.[15]
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| May 23, 2022 | KS_signals | $FWBI SEC Filing 10-Q filed: [rename] In connection with the Merger, AzurRx changed its name to First Wave BioPharm… https://t.co/olX2wlw75b |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://www.azurrx.com/about-us/leadership
- ↑ https://www.crunchbase.com/funding-round/555754fb5508350e23191f3b311d3195
- ↑ http://www.xdata.co/story.php?a=000141588916005478&c=1604191
- ↑ http://www.nasdaq.com/markets/ipos/company/azurrx-biopharma-inc-931278-81303
- ↑ http://www.gastrojournal.org/article/S0016-5085(15)01524-3/fulltext
- ↑ https://www.ncbi.nlm.nih.gov/pubmed/26327131
- ↑ http://www.azurrx.com/news-events/press-releases/2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit
- ↑ http://www.azurrx.com/news-events/press-releases/2015/60-azurrx-announces-addition-of-ed-borkowski-to-the-board-of-directors
- ↑ http://www.azurrx.com/news-events/events
- ↑ https://ipscio.com/licensing-economics-review/protea-azurrx-and-mayoly-spindler-in-may-protea-biosciences-group-inc/
- ↑ http://www.loeb.com/experience-proteabioeuropecapitalstockacquisition
- ↑ http://www.businesswire.com/news/home/20161012005235/en/AzurRx-BioPharma-Announces-Pricing-Initial-Public-Offering
- ↑ http://seekingalpha.com/article/4000740-azurrx-biopharma-ultra-high-risk-ipo
- ↑ http://www.fiercebiotech.com/biotech/azurrx-biopharma-discounts-5m-ipo-as-accelerated-pharma-files-for-19m-offering
- ↑ http://www.azurrx.com/news-events/press-releases/2016/75-azurrx-biopharma-inc-nasdaq-azrx-to-ring-the-nasdaq-stock-market-closing-bell
Top Authors
Verification history
2,728 days ago- View all verifications
